These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1837474)

  • 1. Cause-specific survival advantage shown for hormone therapy for diploid prostate tumors.
    Zincke H
    Oncology (Williston Park); 1991 Jul; 5(7):14, 16. PubMed ID: 1837474
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathological stage C (pT3) prostate cancer treated by radical prostatectomy: clinical implications of DNA ploidy analysis.
    Lieber MM
    Semin Urol; 1990 Nov; 8(4):219-24. PubMed ID: 2284528
    [No Abstract]   [Full Text] [Related]  

  • 3. The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer.
    Häggarth L; Auer G; Busch C; Norberg M; Häggman M; Egevad L
    Scand J Urol Nephrol; 2005; 39(5):387-92. PubMed ID: 16257840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral orchiectomy in the management of stage D-2 prostate cancer.
    Guinan P; Firfer R; Targonski P; Rubenstein M
    Int Surg; 1993; 78(1):73-5. PubMed ID: 8473090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.
    Yossepowitch O
    Eur Urol; 2007 Aug; 52(2):453. PubMed ID: 17674435
    [No Abstract]   [Full Text] [Related]  

  • 6. [Surgical and medical treatment for localized prostate cancer].
    Kawai K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.
    Lerner SE; Blute ML; Zincke H
    J Urol; 1995 Sep; 154(3):1103-9. PubMed ID: 7543608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer.
    Hashine K; Numata K; Azuma K; Sumiyoshi Y; Kataoka M
    Jpn J Clin Oncol; 2005 Nov; 35(11):655-9. PubMed ID: 16275680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation of DNA ploidy in fresh tumor tissues to prognosis of nasopharyngeal carcinoma].
    Han F; Wang HY; Xia YF; Liu MZ; Zhao C; Lu TX
    Ai Zheng; 2007 Sep; 26(9):1015-9. PubMed ID: 17927864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 11. [The prognostic value of flow cytometry in prostatic cancer].
    Matveev BP; Bukharkin BV; Bogatyrev VN; Iurasova IV; Ataev AA; Bocharova OA; Mustia AI
    Urol Nefrol (Mosk); 1994; (4):24-7. PubMed ID: 7985295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
    Lotan Y
    Eur Urol; 2007 Aug; 52(2):453-4. PubMed ID: 17674436
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR; Presti JC; Gill H; Brooks J; Hancock SL
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endocrine therapy versus observation after R0 resection in node positive prostate cancer].
    Kleeberg UR
    Strahlenther Onkol; 2000 Jun; 176(6):293-4. PubMed ID: 10897259
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormone therapy for locally advanced prostate cancer.
    Fowler JE; Bigler SA; White PC; Duncan WL
    J Urol; 2002 Aug; 168(2):546-9. PubMed ID: 12131306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.